drugset
drugset / Trial / NCT06948747

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

NCT06948747 ↗

Phase 1 Completed 49 enrolled AstraZeneca
Non-randomizedFactorialOpen-labelTreatment

Summary

This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants.

Timeline

Start
2025-05-06
Primary completion
2025-10-03
Completion
2025-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5004 Unknown — Oral
Subject Atorvastatin Small molecule 40 mg Oral
Subject Erythromycin Small molecule 500 mg Oral
Subject Repaglinide Small molecule 0.5 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral
Subject Simvastatin Small molecule 20 mg Oral

Indications

No indication recorded.